Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy by Tan, HP et al.
American Joumal of Transplantation 2006; 6: 2409-2417 
Blackwell Munksgaard 
© 2006 The Authors 
Journal compilation © 2006 The American Society of 
Transplantation and the American Society of Transplant Surgeons 
doi: 10.1111/j.1600-6143.2006.01495.x 
Living Donor Renal Transplantation Using 
Alemtuzumab Induction and Tacrolimus Monotherapy 
H. P. Tan*, D. J. Kaczorowski, A. Basu, M. Unruh, 
J. McCauley, C. Wu, J. Donaldson, I. Dvorchik, 
l. Kayler, A. Marcos, P. Randhawa, C. Smetanka, 
T. E. Starzl and R. Shapiro 
The Thomas E. Starzl Transplantation Institute, University 
of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, 
USA 15213 
* Corresponding author: Henkie P Tan, tanhp@upmc.edu 
Alemtuzumab was used as an induction agent in 205 
renal transplant recipients undergoing 207 living donor 
renal transplants. All donor kidneys were recovered la-
paroscopically. Postoperatively, patients were treated 
with tacrolimus monotherapy, and immunosuppres-
sion was weaned when possible. Forty-seven recipi-
ents of living donor renal transplants prior to the in-
duction era who received conventional triple drug im-
munosuppression without antibody induction served 
as historic controls. The mean follow-up was 493 days 
in the alemtuzumab group and 2101 days in the historic 
control group. Actuarial 1-year patient and graft sur-
vival were 98.60/0 and 98.1 % in the alemtuzumab group, 
compared to 93.6% and 91.5% in the control group, 
respectively. The incidence of acute cellular rejection 
(ACR) at 1 year was 6.8% in the alemtuzumab group 
and 17.0% (p < 0.05) in the historic control group. Most 
(81.3%) episodes of ACR in the alemtuzumab group 
were Banff 1 (a or b) and were sensitive to steroid 
pulses for the treatment of rejection. There was no 
cytomegalovirus disease or infection. The incidence 
of delayed graft function was 0%, and the incidence 
of posttransplant insulin-dependent diabetes mellitus 
was 0.5%. This study represents the largest series to 
date of live donor renal transplant recipients undergo-
ing alemtuzumab induction, and confirms the short-
term safety and efficacy of this approach. 
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Introduction 
Alemtuzumab (Campath-1 H) is a humanized anti-CD 52 IgG 
monoclonal antibody that is associated with prolonged de-
pletion of T cells from the peripheral circulation after sys-
temic administration (1, 2). B cells, natural killer cells, and 
monocytes are also depleted by alemtuzumab to a lesser 
extent. While the Food and Drug Administration (FDA) ini-
tially approved it for the treatment of chronic B-ceillympho-
cytic leukemia in 2001 (3, 4), the ability of alemtuzumab to 
deplete lymphocytes from the circulation has generated 
interest in the use of this antibody in solid organ transplan-
tation. While alemtuzumab has not been approved by the 
FDA for use in organ transplantation, the experiences with 
this monoclonal antibody in renal transplantation have been 
promising (2, 5-18). 
We have implemented an immunosuppressive regimen 
based on two key principles: recipient pretransplant lym-
phoid depletion and minimal use of posttransplant steroid-
free immunosuppression (19, 20). Immunosuppressive 
regimens based on these principles are intended to deplete 
pre-operatively pre-existing alloreactive donor-specific T 
celis to prevent acute rejection, while minimizing postoper-
ative immunosuppression with a calcineurin inhibitor (CNIl 
permits interaction between donor and recipient leuko-
cytes. We have previously observed that the use of pre-
conditioning permits spaced weaning of immunosuppres-
sion (8-10, 21). The use of alemtuzumab, compared with 
thymoglobulin has been associated with a substantially 
lower incidence of acute cellular rejection (ACR), but both 
have been associated with a low incidence of infectious 
complications and other adverse events (8-10, 21). Here, 
we present the largest series to date of living donor re-
nal transplantation performed with alemtuzumab induction 
and tacrolimus monotherapy. 
Patients and Methods 
Between January 15, 2003 and December 30, 2005, a total of 207 consec-
utive laparoscopic live donor nephrectomies resulting in 207 living donor re-
nal transplantations in 205 kidney-only recipients (two re-transplants) were 
performed at the University of Pittsburgh Medical Center Starzl Transplanta-
tion Institute (UPMC STI). Forty-six living donor kidney recipients with pre-
vious extra-renal solid organ transplants (n = 43) or positive pretransplant 
cross matches (n = 3) were excluded. Prospective data were collected on 
both donors and recipients. The immunosuppressive regimen was based 
upon pretreatment with intravenous 30 mg Carnpath-1 H (alemtuzumab, 
Berlex, Seattle, WA. USA). Pre-medication was with 1 g of methylpred-
nisolone, which was repeated prior to reperfusion to avoid intra-operative 
hypotension from cytokine release syndrome. Posttransplantation low-dose 
tacrolimus monotherapy (target trough of 10 ng/mL) for the first 100 days 
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posttransplantation was given. starting on postoperative day 1. At approxi-
mately 100 days posttransplantation. the twice-daily dose of tacrolimus was 
consolidated to once a day in recipients with no clinical evidence of ACR 
(i.e increase In creatinine confirmed by biopsy). Protocol biopsies were not 
performed. If the patient continued to do well. the dose was weaned to 
once every other day after another 1 to 4 months. Further weaning was 
continued to three times a week. twice a week or once a week at 2 to 6 
months intervals if the patient continued to do well in the absence of a rising 
creatinine or clinical ACR. Episodes of biopsy-proven ACR were treated with 
a 1 g of Intravenous methylprednisolone or 30 mg intravenous Campath-1 H. 
for steroid-resistant ACR. 
These protocols were approved by the UPMC Innovative Practices Com-
mittee and the UPMC Pharmacy and Therapeutics committee as previously 
described (8-10. 21). Data analysis was approved by the University of Pitts-
burgh Institutional Review Board. As an historical control group. retrospec-
tive data on 47 living donor renal transplants performed between 28 March. 
1 998 and 18 July. 2001 at U PMC STI prior to the thymoglobulin and alem-
tuzumab induction era (after excluding recipients with previous extra-renal 
solid organ transplants. positive pretransplant crossmatches and recipients 
who received any induction therapy) were collected. These recipients re-
ceived no induction therapy and were treated with triple conventional im-
munosuppression consisting of tacrolimus. prednisone and mycophenolate 
mofetil. 
Statistical analysis 
Baseline demographic and laboratory factors were described as means 
(±standard deviation) for continuous variables and as frequency distribu-
tions for dichotomous vanables. Fisher'S exact X. 2 was used to compare 
differences in ACR. human leukocyte antigen (HLA) mismatch. panel re-
active antibodies (PRA»20% and creatinine. Statistical significance of the 
differences between groups was tested using two-sample I-tests or anal-
ysis of variance (ANOVA) for continuous variables and chi square tests for 
categorical variables. 
Actuarial recipient and graft survivals were calculated beginning at the time 
of transplantation. Kidney graft failure was defined as death of recipient. 
removal of the allograft or loss of function requiring return to dialysis. Ac- . 
tuarial Kaplan-Meier survivals were calculated using the Statistical Package 
for the Social Science (SPSS) software and the series was followed until 30 
December. 2005. The magnitude of a factor's association with survival was 
estimated by the Breslow generalized Wilcoxon statistic. a test of the null 
hypothesis that there is no association between the factor and survival. We 
present cumulative recipient and graft survival curves using Kaplan-Meier 
methods. All statistical tests were two-tailed; statistical significance was 
defined by a p < 0.05. 
Results 
Recipient characteristics and survival 
The mean follow-up forthe 205 living donor renal transplant 
recipients that received alemtuzumab induction was 493 ± 
282 days. Of the 205 recipients, 28 (13.7%) had previous 
failed transplants. Eighteen (8.7%) recipients had a 2nd and 
10 (4.9%) recipients had a 3rd to 5th transplant. There were 
4 (1.8%) HIV+, 13 (5.8%) pediatric and 31 (15.1 %) African 
American recipients. The average HLA mismatch was 3.2 
± 1.6, and 6.5% of recipients had a pretransplant PRA ::: 
20%. See Table 1 for detailed recipient characteristics. 
By comparison, none of the patients in the historical con-
trol group was HIV+ at the time of transplantation. In the 
historic control group, HLA matching (mean H LA mismatch 
was 2.9 ± 1.5; HLA A, P = 0.36; HLA B, P = 0.36; HLA DR, 
p = 0.16) and pretransplant PRA ::: 20% (6.4%, p > 0.05) 
were the same in alemtuzumab group. The mean follow-up 
for the historical control group was 2101 ± 640 days. 
Actuarial1-year recipient survival was 98.6% in the group 
receiving alemtuzumab induction and 93.6% (p = 0.187) 
in the historic control group, respectively (see Figu re 1 A). 
Recipient survival in the group that received alemtuzumab 
induction was 98.0% at 493 days mean follow-up. There 
were four deaths in this group (at 192, 345, 725 and 
976 days posttransplantation); three had excellent graft 
Table 1: Characteristics of living donor renal transplant recipients. Two hundred five recipients who received alemtuzumab 
induction with tacrolimus monotherapy were compared to 47 historical control recipients who were transplanted prior to 
the induction era and are on standard triple immunosuppression (tacrolimus. mycophenolate mofetil, and prednisone) 
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Recipients (%) 
Transplants 
Age (years) 
Primary graft 
Re-transplants 
2nd transplants 
3rd to 5th transplants 
HIV+ recipients 
Pediatric recipients 
HLA mismatch 
PRA> 20% 
Mean recipient follow-up (days) 
Actuarial 1-year recipient survival (%) 
*There were two re-transplants in the series. 
"N.S. = nonsignificant, p> 0.05. 
Alemtuzumab induction 
205 (100%) 
207* 
44.1 ± 17.6 
177 (86.3%) 
28 (13.7%) 
18(8.7%) 
10(4.9%) 
4 (1.8%) 
13 (5.8%) 
3.2 ± 1.6 
6.5% 
493 ± 282 
98.6% 
Historical control 
47 (100%) 
47 
46.2 ± 16.9 
40 (85.1%) 
7 (14.8.%) 
7 (14.8%) 
0(0%) 
0(0%) 
3 (6.4%) 
2.9 ± 1.5 
6.4% 
2101 ± 640 
93.6% 
p-value 
N.S.** 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. (p = 0.183) 
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Figure 1: Actuarial patient (A) and 
graft survival (B) of recipients of live 
donor kidney transplantation. The 
drop at the tail end of the alemtuzumab 
curve is associated with a very small 
recipient population at the outer fringe 
of follow-up time with two deaths oc-
curring at posttransplantation days 976 
and 725. The longest patient and graft 
follow-up of the alemtuzumab group 
is 1028 days and mean follow-up 493 
days. 
,'d.,,'," 
function at the time of their death. Two of the deaths were 
related to iatrogenic causes. One patient died of sepsis 
secondary to bowel perforation during an allograft nephrec-
tomy at an outside institution for allograft failure because 
of biopsy-proven recurrent focal segmental glomeruloscle-
rosis (FSGS). Another patient died from sepsis with a func-
tioning allograft after suffering an esophageal perforation 
during an esophagogastroduodenoscopy (EGO); immuno-
suppression was discontinued during sepsis. The 3rd and 
4th deaths were from a myocardial infarction 24 months 
posttransplantation. and from a nonsmall cell lung cancer 
32 months posttransplantation. respectively. These two 
late deaths (at 725 and 976 days posttransplantation) ac-
count for the drop in the tail end of the actuarial recipient 
and graft survival curves (see Figure 1 A,B). Only 16 recipi-
ents had follow-up time> 900 days. However, we strongly 
caution that the acute drop in the tail end may also repre-
sent a serious long-term concern. Clearly, long-term follow-
up is required to demonstrate this. 
Graft survival and function 
Actuarial l-year graft survival was 98.1 % in the alem-
tuzumab and 91.2% in the historic control groups, respec-
tively (see Figure 1 B and Table 2). This was not statistically 
significant (p = 0.067) but the alemtuzumab group tended 
to have improved graft survival. There were a total of nine 
renal allograft losses at follow-up (at 3, 176,345,365,482, 
582, 690, 725 and 976 days posttransplantation). The inci-
dence of delayed graft function (OGF) is 0%. 
Of the patients in the alemtuzumab and the historic con-
trol groups with functioning grafts. the mean creatinine at 
1 year was 1.46 ± 0.51 mg/dL and 1.58 ± 1.23 mg/dL (p > 
0.05), respectively (see Table 2). At a mean of 493 days 
fOllOW-Up, the mean creatinine was 1.47 ± 0.67 mg/dL and 
1.48 ± 0.54 mg/dL in the alemtuzumab and historic control 
groups, respectively. 
Immunosuppression status and frequency of dosing 
At mean 493 days follow-up, of the 205 patients that 
received alemtuzumab induction, 90 (43.9%) recipients 
were on daily (bid and qd) tacrolimus monotherapy. 
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87 (42.4%) recipients had been weaned to spaced-dose 
monotherapy and 21 (10.2%) recipients were on multi-
immunosuppressive drug therapy (a combination of my-
cophenolate mofetil, prednisone or rapamune were added 
to tacrolimus monotherapy because of episodes of ACR) 
(see Table 3). The HLA mismatch for patients who received 
alemtuzumab induction on daily (twice daily or bid and 
once daily or qd) tacrolimus monotherapy versus Spaced-
dose monotherapy was the same (2.98 ± 1.68 vs. 3.24 ± 
1.61, P > 0.05). Of importance in this protocol, at 493 
days mean follow-up. 90% of recipients were still com-
pletely steroid-free since the time of transplantation. The 
frequency of immunosuppression dosing for recipients re-
ceiving tacrolimus monotherapy is presented in Table 4. 
Of the 87 recipients who were weaned to spaced-dose 
monotherapy, 45 (22.0%) recipients were on every other 
day (qod), 35 (17.1 %) recipients were on three times per 
week (3x/week), 4 (2.0%) recipients were on twice per 
week (2 x/week), and 3 (1.5%) recipients were on once per 
week (1 x/week) tacrolimus. A total of six recipients had 
HLA identical donors and their frequencies of tacrolimus 
dosing are as follows (see Table 4): bid (n = 2), qod (n = 
2), 2x/week (n = 1), 1 x/week (n = 1). Of the 167 alem-
tuzumab induction recipients who have::: 6 months follow-
up, the majority of recipients (n = 87, 52.1 %) are on 
spaced-dose monotherapy. We anticipate the number of 
recipients on spaced-dose monotherapy will continue to 
increase over time. 
Incidence and severity of ACR 
In the alemtuzumab group, the cumulative incidences of 
ACR at 1 ,2,3,4,6 and 12 months and at a mean follow-
up of 493 days were 1.5% (n = 3)' 1.5% (n = 3), 2.0% 
(n = 4),2.4% (n = 5), 2.9% (n = 6)' 6.8% (n = 14), and 
10.7% (n = 22), respectively. In the historic control group, 
the cumulative incidences of ACR at 1 . 2. 3. 4, 6 and 12 
months and 493 days were 12.8% (p < 0.05), 12.8% (p < 
0.05), 12.8% (p < 0.05), 17.0% (p < 0.05), 17.0% (p < 
0.05), 17.0% (p < 0.05) and 21.3% (p < 0.05). respec-
tively (see Table 5). The number of recipients with recur-
rent (> 1 episode) ACR in the alemtuzumab versus historic 
control group was 45.5% (10 of 22) versus 50.0% (5 of 10). 
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Table 2: living donor renal transplant recipients graft survival and function 
Alemtuzumab induction Historical control p-value 
No. of recipients 
No. of grafts 
Actuariall-year graft survival (%) 
Creatinine at 1 year (mg/dL) 
Creatinine at 493 days follow-up (mg/dl) 
* N.S. = nonsignificant, p> 0.05. 
205 
207 
98.1 % 
1.46 ± 0.51 
1.47 ± 0.67 
47 
47 
91 .2 % 
1.58 ± 1.23 
1.48 ± 0.54 
N.S. (p = 0.067) 
N.S. 
N.S. 
Table 3: Immunosuppression regimen status and frequency of immunosuppression dosing in living donor 
renal transplant recipients 
No. of recipients 
Daily monotherapy 
Spaced-dose monotherapy 
Multi-immunosuppressive drug therapy 
Alemtuzumab induction 
205 
90 (43.9%) 
87 (42.4%) 
21" (10.2%) 
Historical control 
47 
15 (31.9%) 
N/A 
20 (42.5%) 
"On multiple immunosuppressive drugs (not just tacrolimus monotherapy) because of ACR episodes, a 
combination of mycophenolate mofetil, prednisone or rapamune were added. 
Table 4: Frequency of dosing in 205 recipients receiving alemtuzumab induction and tacrolimus monotherapy 
at mean follow-up of 493 days 
Alemtuzumab induction HLA-identical transplants 
No. of recipients 
Twice daily (bid) 
Once daily (qd) 
Every other day (qod) 
Three times per week (3x/week) 
Twice per week (2 x/week) 
Once per week (1 x/week) 
Multiple immunosuppressive drugs 
205 
15 (7.3%) 
75 (36.6%) 
45 (22.0%) 
35 (17.1 %) 
4 (2.0%) 
3 (1.5%) 
21 (10.2%) 
6 
2 (33.3%) 
2 (33.3%) 
1 (16.7%) 
1 (16.7%) 
Table 5: Incidence of living donor renal transplant recipients with ACR* at mean follow-up of 493 days 
Recipients 
Cumulative recipients with ACR" at 
~1 month** 
~O months 
~P months 
~4 months 
:::6 months 
:::12 months 
At mean follOW-Up of 493 days, cumulative recipients with ACR were 
ACR recipients with> 1 ACR episode 
Weaning attempted 
Preweaning ACR incidence 
Postweaning ACR incidence 
"All ACR were biopsy proven. 
Alemtuzumab induction Historical control p-value 
205 
1.5% (3) 
1.5% (3) 
2.0% (4) 
2.4% (5) 
2.9% (6) 
6.8% (14) 
10.7% (22) 
45.5% (10) 
57.0% (118) 
4.3% (9) 
6.3% (13) 
47 
12.8% (6) 
12.8% (6) 
12.S% (6) 
17.0% (8) 
17.0% (8) 
17.0% (S) 
21.3% (10) 
50.0% (5) 
p < 0.05 
P < 0.05 
P < 0.05 
p < 0.05 
p < 0.05 
P = 0.047 
P < 0.05 
Table 6 detailed the characteristics of the 22 alemtuzumab 
recipients with 32 episodes of ACR. The presence of graft 
failure, and episodes, severity, timing and treatment of 
ACR in the alemtuzumab group is also depicted in Table 6. 
In the 22 alemtuzumab patients with ACR, 5 lost their re-
nal allograft (patient #12 had immunosuppression reduced 
secondary to BK nephropathy with subsequent ACR; pa-
tient #17 died from a myocardial infarction with resultant 
graft loss; patient #22 died from sepsis secondary to an 
esophageal perforation from an EGO with immunosuppres-
sion withdrawn and resultant allograft loss from Banff 3 
ACR; patient #21 and #19 had ACR at 282 and 478 days 
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Table 7: Severity of ACR episodes by Banff score 
Banff score 32 ACR episodes in 22 alemtuzumab recipients 19 ACR episodes in 10 historic control recipients 
Banff 1 a 
Banff 1 b 
Banff 2a 
Banff 2b 
Banff 3 
32(100%) 
14 (43.8%) 
12 (37.5%) 
4 (12.5%) 
1 (3.1%) 
1 (3.1%) 
posttransplantation). Only one patient (#8) had antibody-
mediated rejection (AMR) with evidence of positive diffuse 
peritubular C4d and donor-specific antibody (DSA) identifi-
cation and titer. This patient responded to plasmapheresis 
and intravenous immunoglobulin (IVlg) with resolution of 
her DSA titer. 
Of the recipients who received alemtuzumab induction 
and had weaning of their maintenance immunosuppres-
sion, 9 (4.4%) experienced pre-weaning ACR (ACR prior 
to weaning of immunosuppression) and another 13 (6.3%) 
patients developed ACR after weaning of daily monother-
apy (postweaning ACR) (see Table 5). There were a total of 
32 episodes of biopsy-proven ACR in the 22 alemtuzumab 
recipients with ACR (see Table 7). Most (81.3%) episodes 
of ACR were Banff 1 (a or b) and were sensitive to steroid 
pulses for treatment of rejection. There were 14 (43.8%) 
Banff 1 a and 12 (37.5%) Banff 1 b ACR episodes. Another 
four (12.5%) ACR episodes were graded as Banff 2a and 
one (3.1 %) was graded as Banff 2b. There was one (3.1 %) 
episode of Banff 3 rejection. Banff 2 ACRs were treated 
with a single dose of 30 mg alemtuzumab intravenously 
(22). 
There were 19 episodes of biopsy-proven ACR in the 10 
historic control recipients with ACR (see Table 7). Fifty-
eight percent (11 of 19 episodes) had Banff 1 ACR (6 of 19 
or31.6% had Banff 1a and 5 of 190r 26.3% had Banff 1b), 
36.8% (7 of 19 episodes) had Banff 2 (3 of 19 or 15.7% 
had Banff 2a and 4 of 19 or 21.1 % had Banff 2b) and 5.3% 
(1 of 19 episodes) had Banff 3 ACR. 
A total of six recipients had HLA identical donors in the 
alemtuzumab group. There was no episode of ACR in these 
HLA identical recipients. The incidence of ACR did not ap-
pear to be higher in African Americans [6.5% (2/31) at 
1 year (p > 0.05), and 12.9% (4/31) at 493 days follow-
up]. One of the African Americans who had ACR was 
noncompliant. 
Complications 
At follow-up, there was no recipient with cytomegalovirus 
(CMV) disease or infection. CMV disease was defined as 
the presence of signs and symptoms of tissue injury with 
isolation of virus and/or histopathologic or immunohisto-
chemical evidence of CMV. CMV infection was defined 
by isolation of virus or detection of viral proteins or nu-
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19 (100%) 
6 (316%) 
5 (263%) 
3 (15.7%) 
4 (21.1%) 
1 (5.3%) 
cleic acids in any body fluid or tissue specimen. All recipi-
ents received prophylactic valganciclovir for 6 to 9 months. 
Three (1.5 %) of the 205 recipients developed BK nephropa-
thy and were treated with weaning of immunosuppression 
and cidofivir. One of these three BK nephropathy recipients 
eventually lost her renal allograft. There was no posttrans-
plant Iymphoproliferative disease (PTLD) in the group that 
received alemtuzumab induction. The incidence of recur-
rent FSGS was 5.6% (1/18). 
In the alemtuzumab group, 26 (12.7%) recipients had dia-
betes prior to transplantation. But only one (0.5%) patient 
developed new onset insulin-dependent diabetes mellitus 
posttransplant. Twenty percent (48 of 205) of recipients 
had a pretransplant fasting glucose> 120 mg/dL. In the his-
toric control, 17.0% (8 of 47) of recipients had pretransplant 
diabetic nephropathy, and about 10% developed insulin-
dependent diabetes mellitus posttransplantation. 
With alemtuzumab induction, one vascular thrombosis oc-
curred in this series (this was related to traumatic transec-
tion of the renal vein and artery at the hilum when the re-
cipient woke up despite vascular repair). Ureteral stenosis 
occurred in one patient (0.5%); this was in a HIV+ recipi-
ent. The stenosis was revised with a uretero-ureteral anas-
tomosis to the native ureter, and this recipient continues to 
have an excellent graft function. There also appears to be 
no higher incidence of pulmonary toxicity «1 %), with the 
vast majority of recipients extubated posttransplantation 
not requiring an intensive care unit. 
Neutropenia was treated with subcutaneous injection(s) 
of Neupogen® (Filgrastim, Amgen Inc., Thousand Oaks, 
CA, USA) on an outpatient basis. There were a total of 40 
episodes of neutropenia requiring Neupogen® in the 205 
recipients; 15% of recipients received Neupogen®. Each 
dose of 300 J-lg subcutaneous Neupogen® costs about 
$140. The incidence of readmission to the hospital for any 
reason was < 1 0% within the first 3 months posttransplant. 
The most common reasons were urinary tract infection, de-
hydration, a rising serum creatinine and the need to exclude 
ACR. 
Discussion 
This report, which represents the largest series to date 
of living donor renal transplantation recipients receiving 
American Journal of Transplantation 2006; 6: 2409-2417 
alemtuzumab induction, confirms the short-term safety 
and efficacy of this drug as an induction agent. Despite 
the complexity of the recipient population, which included 
28 re-transplants (8.7% had 2nd transplants, 4.9% had 3rd 
to 5th transplants), 4 HIV+ recipients and 13 pediatric re-
cipients, the incidence of ACR at 1 year was 6.8%, and 
the actuarial 1-year patient and graft survivals were 98.6% 
and 98.1 %, respectively. These short-term survivals are 
superior to those of the US Transplant-Scientific Registry 
of Transplant Recipients (SRTR) database; for year 2002, 
the 1-year unadjusted patient and graft survivals were 
97.6%, and 90.5%, respectively (23). Furthermore, good 
graft function was also observed, with a mean creatinine 
of 1.46 ± 0.51 mg/dL at 1 year and 1.47 ± 0.67 mg/dL at 
mean 493 days follow-up. The group that received alem-
tuzumab induction had a significantly lower incidence of 
ACR (6.8%) than the historic controls (17%) at 1 year (p = 
0.047). Most importantly, the incidence of recipient com-
plications at 1 year, including PTLD (0%). CMV disease 
or infection (0%) and posttransplant insulin-dependent di-
abetes mellitus (0.5%). was exceptionally low. 
Our findings support and extend those of Caine and col-
leagues in 1997 who first employed alemtuzumab as in-
duction therapy in renal transplantation, followed by low-
dose cyclosporine monotherapy (5). These initial results of 
13 patients were promising and prompted further trials to 
study the use of alemtuzumab as an induction agent in 
renal transplantation. A 5-year follow-up study compared 
outcomes in 33 renal transplant recipients who received 
alemtuzumab induction therapy followed by low-dose cy-
closporine monotherapy to 66 renal transplant contempo-
raneous control recipients who received conventional im-
munosuppression consisting of cyclosporine, azathioprine 
and prednisolone (6). While 14% of patients in the alem-
tuzumab group experienced ACR beyond 1-year posttrans-
plant compared to none in the control group, the incidence 
of ACR was similar at 5 years (33.6% in the alemtuzumab 
group vs. 31.5% in the control group). The overall 5-year 
patient (88% vs. 83%) and graft (79% vs. 74%) survival 
rates, as well as the incidence of infectious complications, 
were similar in both alemtuzumab and control group, re-
spectively. They concluded that alemtuzumab allowed sat-
isfactory long-term patient and graft survivals equivalent to 
those seen with standard triple immunosuppression, while 
avoiding steroid therapy. 
In addition, several recent studies have demonstrated that 
alemtuzumab is an effective induction agent in both liv-
ing donor and deceased donor renal transplantation with 
few short-term side effects. Knechtle and colleagues from 
the University of Wisconsin utilized alemtuzumab induction 
therapy followed by sirolimus monotherapy in a pilot study 
involving 29 renal transplant recipients at 3 to 29 months 
of follow-up (11). In this study, there were no infectious 
complications and no evidence of malignancy. However, 8 
(27.6%) of the 29 patients experienced rejection, and while 
the rejection was treated successfully in 7 patients, 1 pa-
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tient experienced graft loss. Of the eight patients that expe-
rienced rejection, five had evidence of humoral rejection. 
More recently, Knechtle and colleagues reported on the 
results of 126 renal allograft recipients who received alem-
tuzumab induction therapy compared with other recipients 
who received either anti-CD25 antibody, thymoglobulin, or 
other induction therapy with a CNI, mycophenolate mofetil 
and prednisone for maintenance (12). The group that re-
ceived alemtuzumab experienced a significantly lower in-
cidence of ACR compared to the other groups, while the 
rates of infection and malignancy were not significantly 
different. Importantly, patients with DGF experienced less 
rejection with alemtuzumab than the control groups and 
had improved graft survival. Kaufman and colleagues (13) 
reported similar results with kidney transplant patients re-
ceiving alemtuzumab (n = 123) or basiliximab (n = 155) in-
duction with a prednisone-free maintenance protocol using 
tacrolimus (6 to 8 ng/ml) and mycophenolate mofetil com-
bination. A lower rate of early «3 months) ACR was ob-
served in the alemtuzumab (4.1 %) versus the basiliximab 
(11.6%) group, but the actual ACR rates for both groups 
in living donor recipients were equivalent at 1 year (alem-
tuzumab = 14.3%, basiliximab = 12.4%). The 1-year ac-
tual recipient and graft survivals among living donor recip-
ients treated with alemtuzumab were 96.7% and 98.9%, 
respectively. 
Kirk et al. reported seven nonsensitized recipients of 
living donor kidneys treated perioperatively with alem-
tuzumab and followed them postoperatively without main-
tenance immunosuppression (14). All recipients devel-
oped reversible ACR within the first month that was char-
acterized by predominantly monocytic infiltrates. These 
episodes were responsive to treatment with steroids or 
sirolimus or both. In a more recent pilot study of five re-
cipients of live donor kidneys treated with perioperative 
alemtuzumab and deoxyspergualin (which has an inhibitory 
effect on monocytes and macrophages) without mainte-
nance immunosuppression, Kirk et al. reported that all five 
recipients developed reversible ACR that was similar in 
timing, histology, and transcriptional profile to that seen 
in patients treated with alemtuzumab alone (15). T-cell de-
pletion combined with deoxyspergualin induces tolerance 
in nonhuman primates but does not appear to induce tol-
erance in humans. It appears that chemokine production 
is not adequately suppressed with alemtuzumab induction 
and that some form of maintenance immunosuppression 
is required with this protocol. 
Recently Flechner and colleagues (7), in a pilot study of 22 
kidney transplant recipients receiving alemtuzumab induc-
tion, sirolimus, and mycophenolate mofetil maintenance 
without CNI and steroids, demonstrated a relatively high 
incidence of ACR (36% at 1 year) and possible pulmonary 
toxicity, raising concerns about the efficacy and safety of 
the protocol. This and other studies point to the impor-
tance of at least an initial period of CNI in recipients re-
ceiving alerntuzumab induction. We did not see a higher 
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incidence of pulmonary toxicity with the vast majority of 
our recipients extubated posttransplantation not requiring 
an intensive care unit. 
A recent randomized controlled clinical trial compared thy-
moglobulin (n = 30), alemtuzumab (n = 30) and daclizumab 
(n = 30) in deceased donor renal transplant recipients 
(16). Induction therapy with alemtuzumab and tacrolimus 
(trough of 4 to 7 ng/mU and mycophenolate mofetil (1 g 
daily) combination maintenance therapy was associated 
with similar 1-year actuarial patient, graft survival and func-
tion (thymoglobulin = 92%,88%, creatinine clearance 80; 
alemtuzumab = 100%, 100%, creatinine clearance 73; da-
clizumab = 88%, 88%, creatinine clearance 81), respec-
tively. The majority (80%) of patients remained steroid-free 
at 1 year posttransplantation. In addition, encouraging ex-
cellent preliminary results have also been obtained with 
alemtuzumab induction in HIV+ recipients (10) and pedi-
atric recipients (17, 18). 
While alemtuzumab depletes both T- and B lymphocytes 
from the peripheral circulation, its effects on monocytes 
are less pronounced, and plasma cells are not effectively 
depleted from the circulation. Accordingly, recent reports 
have described monocyte-predominant ACR (14) as well 
as severe, early acute humoral rejection (24). We did not 
see a higher incidence of early severe acute humoral re-
jection in our patients with tacrolimus monotherapy. The 
importance of CNI requirement in the early posttransplant 
period with alemtuzumab induction was demonstrated in 
the pilot studies by Flechner and Knechtle et al. (7, 11, 12). 
The majority of ACR episodes in this current study was 
Banff 1 a or 1 b, and was successfully treated with a steroid 
bolus. 
The findings in this report have several limitations. While 
this study confirms the short-term safety and efficacy of 
alemtuzumab, long-term follow-up is clearly needed. A 
mean follow-up of 493 ± 282 days in 205 recipients is 
relatively short. The acute drop in the tail end of the Kaplan-
Meier patient and graft survival curves may be related to 
the small number of patients at long-term follow-up. How-
ever, it may also represent a serious long-term concern. 
More careful assessment of graft function with creatinine 
clearance at various time points may provide a more accu-
rate measurement of renal function. Continued follow-up 
will clearly be required to assess long-term graft survival 
and function. The delayed incidence of ACR that occurs 
as lymphocytes return to baseline will need to be mon-
itored closely, as will the rates of late chronic allograft 
nephropathy. Re-population of the profound depletion of 
peripheral blood lymphocytes, monocytes, and NK cells 
by alemtuzumab can take up to 1 year. Knechtle and col-
leagues (2) found lymphocytes reach at least 80% of base-
line values 18 to 24 months post-alemtuzumab induction. It 
IS also hoped that with a lower starting dose of tacrolimus 
progressively weaned over time, a decreased incidence of 
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CNI nephrotoxicity will be observed compared to traditional 
triple immunosuppression. 
The long-term benefits of alemtuzumab induction with 
tacrolimus monotherapy clearly warrant further investiga-
tion. The immunologic mechanisms that permit the ability 
to wean immunosuppression in these patients have yet 
to be elucidated. Additional studies directed at elucidating 
these mechanisms are currently underway (25). It is hoped 
that monitoring of class I and II antibodies by enzyme-linked 
immunoassay and identification of DSAs can potentially 
aid in weaning of immunosuppression and thus decrease 
the incidence of postweaning ACR. We are also in the 
process of assessing both the frequency and function of 
donor-reactive T cells, as well as identifying cytokine gene 
polymorphism and assaying alloantibody titers in recipients 
who have or have not experienced rejection after spaced-
dose weaning. The advisability of empiric immunosuppres-
sion withdrawal in otherwise stable patients remains to be 
established. Given the increased, albeit low, rate of acute 
rejection seen post-weaning in previously stable patients, 
this approach remains investigational. 
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